Indian pharmaceutical manufacturers are exporting massive quantities of unauthorized and overdosed tapentadol to several countries across West Africa [1, 2].
This surge in illicit opioid availability threatens to destabilize regional public health systems by exacerbating a growing addiction crisis. The influx of these substances often bypasses international health regulations, leaving local populations vulnerable to high-potency drugs without medical oversight.
The current trend involves the shipment of tapentadol, a synthetic opioid, which has followed a similar trajectory to tramadol [1, 2]. Previously, tramadol dominated the illicit market in the region, but tapentadol is now appearing in significant volumes on the streets of West African nations [1, 2]. These substances are frequently produced with dosages that exceed international health standards, increasing the risk of overdose and death [1, 2].
Industry analysts said the crisis is driven by a pursuit of profit within a market where demand for opioids is rising [1, 2]. The ease of exportation from India, combined with lax regulatory frameworks in both the exporting and receiving regions, has allowed these shipments to proliferate [1, 2].
International health bodies have designated these specific high-dose versions of the drugs as prohibited substances [1, 2]. Despite these bans, the substances continue to flow into the region through maritime freight and various trade loopholes [1, 2]. The 2026 World Drug Report notes that this pattern of opioid distribution has been a persistent issue since the early 2020s [2].
Local authorities in West Africa face significant challenges in intercepting these shipments due to the volume of trade and the sophistication of the supply chains [1, 2]. Because these drugs are often sold in open-air markets rather than pharmacies, tracking the distribution remains difficult for health officials [1, 2].
“Indian pharmaceutical manufacturers are exporting massive quantities of unauthorized and overdosed tapentadol to several countries across West Africa.”
The shift from tramadol to tapentadol suggests that illicit manufacturers are adapting to regulatory crackdowns by introducing different synthetic opioids to maintain profit margins. This creates a 'whack-a-mole' scenario for West African health authorities, where banning one substance leads to the immediate introduction of another, potentially more dangerous, alternative.
